胆道闭锁儿童肝移植术后90天再入院危险因素分析

doi:10.12372/jcp.2023.22e0452

Abstract

Abstract:

Objective To investigate the 90-day readmission rate and risk factors of children with biliary atresia (BA) after liver transplantation (LT). Methods This retrospective cohort study was conducted in Xinhua Hospital, Renji Hospital and Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine from January 1 to December 31, 2019. Data of children with BA who received LT for the first time were retrospectively analyzed. Patients were divided into readmission group and non-readmission group according to whether they were readmitted within 90 days after LT. The differences between the two groups were compared. Logistic regression was used to analyze the risk factors of 90-day readmission. Results A total of 264 children (female 53.0%) were included, with a median age of 6.9 (5.6-9.4) months. The 90-day readmission rate was 22.0% (58 / 264). Compared with the non-readmission group, the readmission group had higher pediatric end-stage liver disease (PELD) score, higher serum total bile acid level (TBA), higher international normalized ratio (INR), longer length of hospital stays (LOS), lower platelet count and lower psoas muscle area (PMA), and all the difference were statistically significant (P<0.05). Binary logistic regression analysis showed that thrombocytopenia (OR =2.347, 95%CI: 1.154-4.776), TBA (OR =1.058, 95% CI: 1.011-1.106), PMA (OR = 0.615, 95% CI: 0.301-0.989), and LOS (OR= 1.069, 95% CI: 1.031-1.109) were the influencing factors of 90-day readmission after pediatric LT, with statistical significance (P<0.05).Conclusions Children with thrombocytopenia, elevated TBA, lower PMA and long LOS had a higher risk of 90-day readmission after LT.

Key words: readmission, biliary atresia, liver transplantation

WAN Shuangshuang, XU Renying, QIAN Yongbing, HONG Li, FENG Yi. Risk factors of 90-day readmission after liver transplantation in children with biliary atresia[J].Journal of Clinical Pediatrics, 2023, 41(2): 134-139.

Figures/Tables 4

References 29

[1]	Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2019 Annual Data Report: Liver[J]. Am J Transplant, 2021, 21(S2): 208-315.
[2]	Wilson GC, Hoehn RS, Ertel AE, et al. Variation by center and economic burden of readmissions after liver transplantation[J]. Liver Transpl, 2015, 21(7): 953-960. doi: 10.1002/lt.24112
[3]	Pereira AA, Bhattacharya R, Carithers R, et al. Clinical factors predicting readmission after orthotopic liver transplantation[J]. Liver Transpl, 2012, 18(9): 1037-1045. doi: 10.1002/lt.23475
[4]	Paterno F, Wilson GC, Wima K, et al. Hospital utilization and consequences of readmissions after liver transplantation[J]. Surgery, 2014, 156(4): 871-878. doi: 10.1016/j.surg.2014.06.018
[5]	Berman K, Tandra S, Forssell K, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease[J]. Clin Gastroenterol Hepatol, 2011, 9(3): 254-259. doi: 10.1016/j.cgh.2010.10.035
[6]	中华医学会小儿外科学分会肝胆外科学组,中国医师协会器官移植医师分会儿童器官移植学组. 胆道闭锁诊断及治疗指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(11): 2435-2440.
[7]	De Onis M, Garza C, Onyango AW, et al. WHO growth standards for infants and young children[J]. Arch Pediatr, 2009, 16(1): 47-53. doi: 10.1016/j.arcped.2008.10.010 pmid: 19036567
[8]	Mcdiarmid SV, Anand R, Lindblad AS. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation[J]. Transplantation, 2002, 74(2): 173-181. pmid: 12151728
[9]	中国成人血小板减少症急诊管理共识专家组. 中国成人血小板减少症急诊管理专家共识[J]. 中华急诊医学杂志, 2022, 31(2):161-168.
[10]	Rayar M, Webber CE, Nayiager T, et al. Sarcopenia in children with acute lymphoblastic leukemia[J]. J Pediatr Hematol Oncol, 2013, 35(2): 98-102. doi: 10.1097/MPH.0b013e318279eea2
[11]	Mager DR, Hager A, Ooi PH, et al. Persistence of sarcopenia after pediatric liver transplantation is associated with poorer growth and recurrent hospital admissions[J]. JPEN J Parenter Enteral Nutr, 2019, 43(2): 271-280. doi: 10.1002/jpen.1414 pmid: 30035306
[12]	Barbero-Becerra VJ, López-Méndez I, Romo-Araiza A, et al. Sarcopenia in chronic liver diseases: a translational overview[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(5): 355-366. doi: 10.1080/17474124.2020.1757427
[13]	Dedhia PH, White Y, Dillman JR, et al. Reduced paraspinous muscle area is associated with post-colectomy complications in children with ulcerative colitis[J]. J Pediatr Surg, 2018, 53(3): 477-482. doi: S0022-3468(17)30573-0 pmid: 29103786
[14]	Suzuki D, Kobayashi R, Sano H, et al. Sarcopenia after induction therapy in childhood acute lymphoblastic leukemia: its clinical significance[J]. Int J Hematol, 2018, 107(4): 486-489. doi: 10.1007/s12185-017-2388-9 pmid: 29234981
[15]	Mangus RS, Bush WJ, Miller C, et al. Severe sarcopenia and increased fat stores in pediatric patients with liver, kidney, or intestine failure[J]. J Pediatr Gastroenterol Nutr, 2017, 65(5): 579-583. doi: 10.1097/MPG.0000000000001651
[16]	Erkul O, Cekic AB, Cansu A, et al. Effects of sarcopenia on postoperative outcomes in patients who underwent gastrectomy for gastric cancer[J]. J Surg Res, 2022, 274: 196-206. doi: 10.1016/j.jss.2021.12.051 pmid: 35183030
[17]	Wong L, Kent AB, Lee D, et al. Low muscle mass and early hospital readmission post-kidney transplantation[J]. Int Urol Nephrol, 2022, 54(8):1977-1986. doi: 10.1007/s11255-021-03085-1
[18]	Gibson DJ, Burden ST, Strauss BJ, et al. The role of computed tomography in evaluating body composition and the influence of reduced muscle mass on clinical outcome in abdominal malignancy: a systematic review[J]. Eur J Clin Nutr, 2015, 69(10): 1079-1086. doi: 10.1038/ejcn.2015.32 pmid: 25782424
[19]	李尚书, 刘群, 黄丽雯. 慢性肝病血小板减少的原因[J]. 中国肝脏病杂志(电子版), 2021, 13(2): 24-28.
[20]	Benner C, Spence KT, Childers WK. Preoperative anemia is a risk factor for poor perioperative outcomes in ventral hernia repair[J]. Hernia, 2022, 26(6):1599-1604. doi: 10.1007/s10029-022-02572-3 pmid: 35175459
[21]	Son YJ, Kim BH. Prevalence of anemia and its influence on hospital readmissions and emergency department visits in outpatients with heart failure[J]. Eur J Cardiovasc Nurs, 2017, 16(8): 687-695. doi: 10.1177/1474515117710154
[22]	Li WT, Klement MR, Foltz C, et al. Highlighting the roles of anemia and aspirin in predicting ninety-day readmission following aseptic revision total joint arthroplasty[J]. J Arthroplasty, 2020, 35(2): 490-494. doi: S0883-5403(19)30845-9 pmid: 31606291
[23]	Hedaya MS, El Moghazy WM, Yasutomo Y, et al. Is biliary bile acid a good predictor for acute cellular rejection in living donor liver transplantation?[J]. Hepatobiliary Pancreat Dis Int, 2009, 8(5): 474-478.
[24]	Vilca Melendez H, Rela M, Setchell K D, et al. Bile acids analysis: a tool to assess graft function in human liver transplantation[J]. Transpl Int, 2004, 17(6): 286-292. pmid: 15205724
[25]	Wu JF, Boo YA, Ho MC, et al. Serum bile acid levels assist the prediction of biliary stricture and survival after liver transplantation in children[J]. Eur J Pediatr, 2021, 180(8): 2539-2547. doi: 10.1007/s00431-021-04098-9
[26]	Capparelli MA, Ayarzabal VH, Halac ET, et al. Preoperative risk factors for the early failure of the Kasai portoenterostomy in patients with biliary atresia[J]. Pediatr Surg Int, 2021, 37(9): 1183-1189. doi: 10.1007/s00383-021-04933-y
[27]	Donzé J, Aujesky D, Williams D, et al. Potentially avoidable 30-day hospital readmissions in medical patients: derivation and validation of a prediction model[J]. JAMA Intern Med, 2013, 173(8): 632-638. doi: 10.1001/jamainternmed.2013.3023 pmid: 23529115
[28]	Jang SJ, Yeo I, Feldman DN, et al. Associations between hospital length of stay, 30-day readmission, and costs in st-segment-elevation myocardial infarction after primary percutaneous coronary intervention: a nationwide readmissions database analysis[J]. J Am Heart Assoc, 2020, 9(11): e015503. doi: 10.1161/JAHA.119.015503
[29]	姜泽东, 严盛. 加速康复外科的现状及其在肝移植中的应用[J]. 中华普通外科杂志, 2021, 36(11): 884-888.

项目	再入院组(n=58)	未再入院组(n=206)	统计量	P
女[n(%)]	29(50.0)	111(53.9)	χ²=0.27	0.601
年龄[M(P₂₅~P₇₅)]/月	7.4(6.1~10.0)	6.7(5.6~9.2)	Z=1.59	0.111
体质量(x±s)/kg	7.2±1.5	7.3±1.9	t=0.31	0.759
WAZ(x±s)	-1.5±1.3	-1.3±1.4	t=0.99	0.324
身高(x±s)/cm	67.5±5.3	67.6±7.1	t=0.13	0.899
HAZ(x±s)	-1.3±1.4	-1.1±1.7	t=1.02	0.309
生长发育落后[n(%)]	24(41.4)	72(35.0)	χ²=0.81	0.369
PELD评分[M(P₂₅~P₇₅)]	17.0(13.0~22.0)	14.0(11.0~19.0)	Z=2.40	0.017
PELD评分>15[n(%)]	34(58.6)	87(42.2)	χ²=4.90	0.027
WBC[M(P₂₅~P₇₅)]/×10⁹·L^-1	6.5 (4.2~9.0)	6.9 (4.7~ 10.1)	Z=0.67	0.501
Hb(x±s)/g·L^-1	84.2±17.1	86.6±14.9	t=1.05	0.296
PLT [M(P₂₅~P₇₅)]/×10⁹·L^-1	131.0(86.0~179.0)	148.0(104.0~211.0)	Z=2.04	0.041
PLT<100×10⁹·L^-1[n(%)]	22(37.9)	49(23.8)	χ²=4.61	0.032
白蛋白(x±s)/g·L^-1	32.4±7.3	33.7±6.6	t=1.22	0.224
总蛋白(x±s)/g·L^-1	48.2±6.4	48.3±7.1	t=0.084	0.933
ALT(x±s)/U·L^-1	151.3±31.3	145.1±34.2	t=1.24	0.217
AST(x±s)/U·L^-1	201.5±31.2	198.0±35.2	t=0.68	0.495
总胆红素[M(P₂₅~P₇₅)]/μmol·L^-1	104.0(75.0~136.0)	94.0(63.0~129.0)	Z=1.80	0.072
直接胆红素[M(P₂₅~P₇₅)]/μmol·L^-1	63.0(51.0~80.0)	60.0(39.0~76.0)	Z=1.52	0.128
血清总胆汁酸[M(P₂₅~P₇₅)]/μmol·L^-1	10.0(5.4~15.0)	8.0(4.9~11.0)	Z=2.18	0.030
碱性磷酸酶[M(P₂₅~P₇₅)]/U·L^-1	133.0(82.0~194.0)	141.0(88.0~198.0)	Z=0.79	0.432
γ-GT[M(P₂₅~P₇₅)]/U·L^-1	74.8(31.8~116.0)	77.0(41.0~124.0)	Z=0.72	0.474
尿素氮[M(P₂₅~P₇₅)]/mmol·L^-1	3.0(2.0~4.2)	2.5(1.8~3.3)	Z=1.30	0.194
血肌酐(x±s)/μmol·L^-1	17.7±4.8	16.4±4.3	t=1.96	0.051
INR(x±s)	2.0±0.4	1.8±0.4	t=2.02	0.045

项目	再入院组(n=58)	未再入院组(n=206)	统计量	P
CT人体成分分析（L₃）
腰肌面积(x±s)/cm²	2.4±0.6	2.6±0.9	t=2.00	0.048
棘旁肌肉面积(x±s)/cm²	5.1±1.2	5.2±1.6	t=0.28	0.778
总肌肉面积(x±s)/cm²	7.5±1.6	7.9±2.2	t=0.97	0.334
皮下脂肪面积[M(P₂₅~P₇₅)]/cm²	12.8(9.0~19.9)	13.4(9.6~18.5)	Z=0.06	0.950
内脏脂肪面积[M(P₂₅~P₇₅)]/cm²	4.9(3.0~6.7)	4.4(3.0~7.1)	Z=0.46	0.647
总脂肪面积[M(P₂₅~P₇₅)]/cm²	18.2(14.5~26.7)	19.4(12.8~26.2)	Z=0.45	0.656
临床结局
ICU时间[M(P₂₅~P₇₅)]/h	116.0(93.0~145.0)	116.0(92.0~139.0)	Z=1.27	0.203
住院时间[M(P₂₅~P₇₅)]/d	19.0(15.0~31.0)	16.0(14.0~20.0)	Z=3.54	<0.001
术后1年内死亡[n(%)]	2(3.4)	2(1.0)	-	0.211^1）

变量	偏回归系数	标准误	Wald χ²	OR	95%CI	P
常数项	?3.664	0.535	46.890	0.026	-	-
PLT<100×10⁹·L^-1	0.853	0.362	5.546	2.347	1.154~4.776	0.019
血清总胆汁酸/μmol·L^-1	0.056	0.023	6.032	1.058	1.011~1.106	0.014
腰肌面积/cm²	?0.499	0.270	3.432	0.615	0.301~0.989	0.048
住院时间/d	0.067	0.019	12.763	1.069	1.031~1.109	<0.001

Risk factors of 90-day readmission after liver transplantation in children with biliary atresia

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 29

Related Articles 6

Metrics

Comments

Recommended 0

[1]	WU Bo, TIAN Xinbei, LU Ying, DU Jun, XIAO Yongtao. Expression and significance of cadherin-11 in liver of children with biliary atresia [J]. Journal of Clinical Pediatrics, 2022, 40(2): 134-138.
[2]	TIAN Xinbei, CHEN Shanshan, WANG Weipeng, et al. Effect of macrophage knockout on cholestasis in mice with bile duct ligation [J]. Journal of Clinical Pediatrics, 2021, 39(7): 520-.
[3]	YU Ronghua, WANG Yizhong, ZHANG Ting. Clinical characteristics of infantile liver disease [J]. Journal of Clinical Pediatrics, 2021, 39(1): 2-.
[4]	MA Xin, ZHU Dan, GONG Youzhe, WANG Meijuan, JIN Meng, ZHONG Xuemei. Clinical study of recurrent hyperammonemia caused by argininosuccinic aciduria [J]. Journal of Clinical Pediatrics, 2019, 37(7): 530-.
[5]	Bai Meirong, YU Xianxian. Progress in research of Hedgehog pathway in the pathogenesis of congenital biliary atresia [J]. Journal of Clinical Pediatrics, 2019, 37(6): 475-.
[6]	ZHAO Jinlei, FAN Xiaoge, JIN Sanding, LI Ping, ZHANG Hecheng. Heat shock protein 70 in liver fibrosis in infants with biliary atresia and its impact on prognosis　 [J]. , 2017, 35(2): 106-.